Biopharmaceutical Contract Manufacturing Market - Global Forecast To 2030
商品番号 : SMB-43103
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年8月 |
| ページ数 | 383 |
| 図表数 | 479 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
この調査レポートでは、バイオ医薬品受託製造市場を、サービス（製造、製剤・充填・仕上げ、包装・ラベル作成、その他）、タイプ（生物学的製剤原料製造および生物学的製剤製造）、事業規模（臨床および商業事業）、ソース（哺乳類および非哺乳類発現システム）、治療領域（腫瘍学、自己免疫疾患、代謝性疾患、心血管疾患、神経学、感染症、その他治療領域）、分子タイプ（モノクローナル抗体、抗体薬物複合体、細胞・遺伝子治療、ワクチン、治療用ペプチド・タンパク質、その他分子）、地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分類しています。
本レポートは、バイオ医薬品受託製造市場の成長に影響を与える主要な要因（成長促進要因、阻害要因、課題、機会など）を包括的に分析しています。主要業界プレーヤーの詳細な分析も含まれており、事業概要、製品、ソリューション、主要戦略、そして協業、パートナーシップ、契約に関する洞察を提供しています。さらに、バイオ医薬品受託製造市場における新規承認・上市、合併・買収、その他の重要な活動に関する最近の動向についても取り上げています。
The global biopharmaceutical contract manufacturing market is expected to reach USD 34.15 billion by 2030 from an estimated USD 22.40 billion in 2025, at a CAGR of 8.8% from 2025 to 2030. This growth in the biopharmaceutical contract manufacturing market is primarily driven by advancements in manufacturing technologies and a growing emphasis on personalized medicine. However, evolving regulations may pose challenges that could limit market expansion.
世界のバイオ医薬品受託製造市場は、2025年の推定224億米ドルから2030年には341億5000万米ドルに達し、2025年から2030年にかけて年平均成長率（CAGR）8.8%で成長すると予測されています。バイオ医薬品受託製造市場におけるこの成長は、主に製造技術の進歩と個別化医療への関心の高まりによって牽引されています。しかしながら、規制の進化は市場拡大を制限する可能性のある課題をもたらす可能性があります。
The monoclonal antibodies segment accounted for the largest share of the biopharmaceutical contract manufacturing market in 2024.
The biopharmaceutical contract manufacturing market is segmented by molecule type into monoclonal antibodies (mAbs), cell & gene therapy, antibody-drug conjugates, vaccines, therapeutic peptides & proteins, and other molecules. The mAbs segment leads the market due to the rising prevalence of chronic disorders like cancer and autoimmune diseases, driving the demand for targeted therapies. Monoclonal antibodies are preferred in clinical practice for their precision in targeting specific disease pathways. Government support for mAb research has encouraged biopharmaceutical firms to expand their pipelines, increasing the number of mAb candidates in clinical trials. Consequently, contract manufacturing organizations are experiencing a growing demand for their services to produce these advanced biologics efficiently and cost-effectively.
The mammalian expression systems segment dominated the market in 2024.
The mammalian expression systems segment dominates the global biopharmaceutical contract manufacturing market, primarily due to its critical role in creating complex biologics like monoclonal antibodies. This dominance stems from the ability of mammalian cell platforms to perform intricate post-translational modifications, enhancing treatment effectiveness. The rising demand for advanced biologics and increased investments in cell culture technologies have further solidified this segment. Contract manufacturing organizations are expanding their mammalian cell culture capabilities and adopting advanced technologies to improve yield and quality. As the pipeline for biologics grows, the mammalian expression systems segment is expected to continue driving growth and innovation in biopharmaceutical manufacturing.
Europe accounted for the second-largest share of the market from 2025 to 2030.
The biopharmaceutical contract manufacturing market in Europe is the second largest during the forecast period, driven by rising investments in biologics such as monoclonal antibodies and cell & gene therapies, along with expansions in biomanufacturing capacity. The region is a hub for innovation, focusing on advanced technologies that enhance quality and efficiency. For example, in March 2023, Lonza launched a cGMP manufacturing site for large-scale drug production, underscoring Europe’s commitment to meeting the global demand for complex biologics and attracting pharmaceutical and biotech firms seeking top-tier contract manufacturing services.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (70%) and Demand Side (30%)
- By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
List of Key Companies Profiled in the Report:
Key players in the biopharmaceutical contract manufacturing market include Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Catalent, Inc. (US), Samsung Biologics (South Korea), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holdings Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), GenScript Biotech Corporation (US), AGC Inc. (Japan), Merck KGaA (Germany), JSR Corporation (Japan), IDT Biologika (Germany), Ajinomoto Bio-Pharma (Japan), Agilent Technologies, Inc. (US), and Asahi Kasei Corporation (Japan).
Research Coverage:
This research report categorizes the biopharmaceutical contract manufacturing market by service (manufacturing, formulation & fill-finish, packaging & labeling, and other services), type (biologic drug substance manufacturing and biologic drug product manufacturing), scale of operation (clinical and commercial operations), source (mammalian and non-mammalian expression systems), therapeutic area (oncology, autoimmune diseases, metabolic diseases, cardiovascular diseases, neurology, infectious diseases, and other therapeutic areas), molecule type (monoclonal antibodies, antibody-drug conjugates, cell & gene therapy, vaccines, therapeutic peptides & proteins, and other molecules), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa).
The report provides a comprehensive analysis of the key factors affecting the growth of the biopharmaceutical contract manufacturing market, including drivers, restraints, challenges, and opportunities. It includes an in-depth examination of major industry players, offering insights into their business overviews, products, solutions, and key strategies, as well as their collaborations, partnerships, and agreements. Additionally, the report highlights recent developments related to new approvals and launches, mergers and acquisitions, and other significant activities in the biopharmaceutical contract manufacturing market.
Key Benefits of Buying the Report:
The report will assist both market leaders and new entrants by providing accurate revenue estimates for the overall biopharmaceutical contract manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape, enabling them to better position their businesses and develop effective go-to-market strategies. Additionally, this report will offer insights into the market’s dynamics, including key drivers, constraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising demand for outsourcing services, increasing demand for biologics & biosimilars, increased focus on personalized medicine, industrial collaborations for drug discovery and development/strategic partnerships and collaborations, and advancements in manufacturing technologies), restraints (challenges complying with regulatory reforms), opportunities (rising demand for cell & gene therapy, emerging countries market, and strong emphasis on drug development), and challenges (challenges to meet reformed regulations) influencing the growth of the market.
- Service Development/Innovation: Detailed insights on the upcoming technologies and research & development activities in the biopharmaceutical contract manufacturing market.
- Market Development: The report provides comprehensive information about profitable markets by analyzing them across various regions.
- Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the biopharmaceutical contract manufacturing market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, service launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the biopharmaceutical contract manufacturing market.
Table of Contents
1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 STUDY SCOPE 35
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 35
1.3.2 INCLUSIONS & EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 37
1.4 CURRENCY CONSIDERED 37
1.5 STAKEHOLDERS 37
1.6 SUMMARY OF CHANGES 38
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.1.1 SECONDARY DATA 40
2.1.1.1 Objectives of secondary research 40
2.1.1.2 Key data from secondary sources 41
2.1.2 PRIMARY DATA 41
2.1.2.1 Breakdown of primaries (supply- and demand-side participants) 42
2.1.2.2 Key objective of primary research 42
2.2 MARKET ESTIMATION 43
2.2.1 GLOBAL MARKET ESTIMATION 43
2.2.1.1 Company revenue analysis (bottom-up approach) 43
2.2.1.1.1 Revenue share analysis of Thermo Fisher Scientific Inc. 44
2.2.1.2 MnM repository analysis 45
2.2.1.3 Primary interviews 46
2.2.2 INSIGHTS OF PRIMARY EXPERTS 46
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 47
2.3 MARKET GROWTH RATE PROJECTIONS 48
2.4 DATA TRIANGULATION 49
2.5 STUDY ASSUMPTIONS 50
2.6 RESEARCH LIMITATIONS 51
2.7 RISK ANALYSIS 51
3 EXECUTIVE SUMMARY 52
4 PREMIUM INSIGHTS 56
4.1 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW 56
4.2 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION AND COUNTRY (2025) 57
4.3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE,
BY THERAPEUTIC AREA, 2025 VS. 2030 57
4.4 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2025 VS. 2030 (USD MILLION) 58
4.5 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
GEOGRAPHIC GROWTH OPPORTUNITIES 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Increasing outsourcing of biologics manufacturing among biopharmaceutical companies 61
5.2.1.2 Rising demand for biologics and biosimilars 62
5.2.1.3 Growing focus on personalized medicine 64
5.2.1.4 Increasing collaborations between pharmaceutical companies and biologics CMOs 65
5.2.1.5 Advancements in manufacturing technologies 66
5.2.2 RESTRAINTS 66
5.2.2.1 Intellectual property rights issues 66
5.2.3 OPPORTUNITIES 67
5.2.3.1 Rising demand for cell & gene therapy 67
5.2.3.2 Significant growth opportunities offered by emerging countries 68
5.2.3.3 Expansion of biologics manufacturing capacities by CMOs 68
5.2.4 CHALLENGES 69
5.2.4.1 Strict regulations 69
5.3 TECHNOLOGY ANALYSIS 70
5.3.1 KEY TECHNOLOGIES 70
5.3.1.1 Single-use technologies 70
5.3.1.2 Continuous bioprocessing 70
5.3.2 COMPLEMENTARY TECHNOLOGIES 70
5.3.2.1 Robotics and automation in fill-finish 70
5.3.2.2 CRISPR & gene editing tools 71
5.3.3 ADJACENT TECHNOLOGIES 71
5.3.3.1 3D bioprinting & microfluidics 71
5.3.3.2 Biosensors & real-time analytics 71
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72
5.5 PRICING ANALYSIS (QUALITATIVE) 73
5.6 VALUE CHAIN ANALYSIS 74
5.7 ECOSYSTEM ANALYSIS 75
5.8 PATENT ANALYSIS 77
5.9 REGULATORY ANALYSIS 79
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
5.9.2 REGULATORY LANDSCAPE 82
5.10 KEY CONFERENCES & EVENTS, 2025–2026 85
5.11 PORTER’S FIVE FORCES ANALYSIS 86
5.11.1 THREAT OF NEW ENTRANTS 87
5.11.2 THREAT OF SUBSTITUTES 87
5.11.3 BARGAINING POWER OF SUPPLIERS 87
5.11.4 BARGAINING POWER OF BUYERS 87
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 87
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 88
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 88
5.12.2 BUYING CRITERIA 89
5.13 INVESTMENT & FUNDING SCENARIO 90
5.14 IMPACT OF AI/GEN AI ON BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET 91
5.15 IMPACT OF 2025 US TARIFFS ON BIOPHARMACEUTICAL CONTRACT
MANUFACTURING MARKET 92
5.15.1 INTRODUCTION 92
5.15.2 KEY TARIFF RATES 93
5.15.3 PRICE IMPACT ANALYSIS 94
5.15.4 IMPACT ON COUNTRY/REGION 95
5.15.4.1 US 95
5.15.4.2 Europe 95
5.15.4.3 APAC 96
5.15.5 IMPACT ON UPSTREAM INDUSTRIES 96
6 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE 97
6.1 INTRODUCTION 98
6.2 MANUFACTURING 98
6.2.1 SHIFT TOWARD CONTINUOUSLY IMPROVING SINGLE-USE TECHNOLOGIES TO DRIVE MARKET 98
6.3 FORMULATION & FILL-FINISH 102
6.3.1 CRITICAL ROLE OF FORMULATION & FILL-FINISH IN BIOLOGICS MANUFACTURING TO DRIVE MARKET GROWTH 102
6.4 PACKAGING & LABELING 105
6.4.1 IMPORTANCE OF PACKAGING & LABELING IN ENSURING SAFETY AND EFFECTIVENESS TO SUPPORT MARKET GROWTH 105
6.5 OTHER SERVICES 108
7 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE 112
7.1 INTRODUCTION 113
7.2 BIOLOGIC DRUG SUBSTANCE MANUFACTURING 113
7.2.1 INCREASING DEMAND FOR BIOTECHNOLOGY PRODUCTS TO DRIVE MARKET 113
7.3 BIOLOGIC DRUG PRODUCT MANUFACTURING 117
7.3.1 INCREASING R&D COST AND PROCESS COMPLEXITY TO DRIVE DEMAND FOR CONTRACT MANUFACTURING FOR BIOLOGIC DRUG PRODUCTS 117
8 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION 121
8.1 INTRODUCTION 122
8.2 COMMERCIAL OPERATIONS 122
8.2.1 INCREASING APPROVALS OF BIOLOGICS TO SUPPORT MARKET GROWTH 122
8.3 CLINICAL OPERATIONS 126
8.3.1 INCREASING NUMBER OF CLINICAL TRIALS FOR TARGETED THERAPIES TO DRIVE MARKET 126
9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE 130
9.1 INTRODUCTION 131
9.2 MAMMALIAN EXPRESSION SYSTEMS 131
9.2.1 VERSATILE THERAPEUTIC DIVERSITY OF MAMMALIAN EXPRESSION SYSTEMS TO DRIVE MARKET 131
9.3 NON-MAMMALIAN EXPRESSION SYSTEMS 135
9.3.1 INCREASING DEMAND FOR BIOLOGICS VACCINES TO
SUPPORT MARKET GROWTH 135
10 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE 140
10.1 INTRODUCTION 141
10.2 MONOCLONAL ANTIBODIES 141
10.2.1 GROWING APPROVALS FOR MABS TO PROPEL MARKET 141
10.3 CELL & GENE THERAPY 144
10.3.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET 144
10.4 ANTIBODY-DRUG CONJUGATES 148
10.4.1 INCREASING INVESTMENTS IN BIOLOGICS TO SUPPORT MARKET GROWTH 148
10.5 VACCINES 151
10.5.1 INCREASING DEMAND FOR VACCINES TO DRIVE MARKET 151
10.6 THERAPEUTIC PEPTIDES & PROTEINS 155
10.6.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO SUPPORT MARKET GROWTH 155
10.7 OTHER MOLECULES 159
11 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA 163
11.1 INTRODUCTION 164
11.2 ONCOLOGY 164
11.2.1 INCREASED APPROVALS AND LAUNCH OF BIOLOGICS FOR ONCOLOGY TO DRIVE MARKET 164
11.3 AUTOIMMUNE DISEASES 168
11.3.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET 168
11.4 CARDIOVASCULAR DISEASES 171
11.4.1 DEVELOPMENT OF NEW TREATMENT OPTIONS TO SUPPORT MARKET GROWTH 171
11.5 METABOLIC DISEASES 174
11.5.1 INCREASING PREVALENCE OF METABOLIC DISEASES TO DRIVE ADOPTION OF BIOLOGICS 174
11.6 INFECTIOUS DISEASES 178
11.6.1 RISING EPIDEMIC OUTBREAKS TO SUPPORT MARKET GROWTH 178
11.7 NEUROLOGY 181
11.7.1 HIGH BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET 181
11.8 OTHER THERAPEUTIC AREAS 184
12 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION 188
12.1 INTRODUCTION 189
12.2 NORTH AMERICA 189
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 190
12.2.2 US 196
12.2.2.1 Presence of large number of FDA-approved manufacturing facilities to favor market growth 196
12.2.3 CANADA 199
12.2.3.1 Rising government funding for drug development to support market growth 199
12.3 EUROPE 202
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 202
12.3.2 GERMANY 207
12.3.2.1 Rapidly growing pharmaceutical market to drive market 207
12.3.3 UK 210
12.3.3.1 Rising investments in drug development to favor market growth 210
12.3.4 FRANCE 213
12.3.4.1 Availability of funds from government and private organizations for domestic drug development to support market growth 213
12.3.5 ITALY 216
12.3.5.1 Rising commercial drug development pipeline to drive market 216
12.3.6 SPAIN 219
12.3.6.1 Rising R&D expenditure to propel market 219
12.3.7 SWITZERLAND 222
12.3.7.1 Strong R&D investments and infrastructure expansion to bolster biotech manufacturing 222
12.3.8 IRELAND 225
12.3.8.1 Robust R&D growth and CDMO capacity expansion to fuel pharma manufacturing 225
12.3.9 REST OF EUROPE 228
12.4 ASIA PACIFIC 231
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 231
12.4.2 CHINA 237
12.4.2.1 Low manufacturing cost and high demand for medicines to favor market growth 237
12.4.3 JAPAN 241
12.4.3.1 Growing demand for biosimilars to drive growth 241
12.4.4 INDIA 244
12.4.4.1 Increasing pharma R&D activities and government funding for biotechnology industry to support market growth 244
12.4.5 SOUTH KOREA 247
12.4.5.1 Increasing R&D activities for drug development to drive market 247
12.4.6 REST OF ASIA PACIFIC 250
12.5 LATIN AMERICA 253
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 253
12.5.2 BRAZIL 258
12.5.2.1 Growing pharmaceutical industry to drive market 258
12.5.3 MEXICO 261
12.5.3.1 Regulatory Improvements to support market growth 261
12.5.4 REST OF LATIN AMERICA 264
12.6 MIDDLE EAST 267
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 267
12.6.2 GCC COUNTRIES 271
12.6.2.1 Substantial opportunities fueled by strong government support to boost growth 271
12.6.3 REST OF MIDDLE EAST 274
12.7 AFRICA 278
12.7.1 EFFORTS TO IMPROVE LOCAL PHARMACEUTICAL PRODUCTION TO BOOST MARKET 278
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 278
13 COMPETITIVE LANDSCAPE 283
13.1 OVERVIEW 283
13.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2022−2025 283
13.3 REVENUE ANALYSIS, 2020–2024 285
13.4 MARKET SHARE ANALYSIS, 2024 286
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 289
13.5.1 STARS 289
13.5.2 EMERGING LEADERS 289
13.5.3 PERVASIVE PLAYERS 289
13.5.4 PARTICIPANTS 289
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 291
13.5.5.1 Company footprint 291
13.5.5.2 Region footprint 292
13.5.5.3 Service type footprint 293
13.5.5.4 Molecule type footprint 294
13.5.5.5 Therapeutic area footprint 295
13.6 COMPANY EVALUATION MATRIX: SMES/STARTUPS, 2024 296
13.6.1 PROGRESSIVE COMPANIES 296
13.6.2 RESPONSIVE COMPANIES 296
13.6.3 DYNAMIC COMPANIES 296
13.6.4 STARTING BLOCKS 296
13.6.5 COMPETITIVE BENCHMARKING: SMES/STARTUPS, 2024 298
13.6.5.1 Detailed list of key SMEs/startups 298
13.6.5.2 Competitive benchmarking of key emerging players/startups 299
13.7 COMPANY VALUATION & FINANCIAL METRICS 300
13.7.1 FINANCIAL METRICS 300
13.7.2 COMPANY VALUATION 300
13.8 BRAND/PRODUCT COMPARISON 301
13.9 COMPETITIVE SCENARIO 302
13.9.1 SERVICE LAUNCHES 302
13.9.2 DEALS 302
13.9.3 EXPANSIONS 303
14 COMPANY PROFILES 304
14.1 KEY PLAYERS 304
14.1.1 LONZA 304
14.1.1.1 Business overview 304
14.1.1.2 Services offered 306
14.1.1.3 Recent developments 307
14.1.1.3.1 Deals 307
14.1.1.3.2 Expansions 308
14.1.1.4 MnM view 308
14.1.1.4.1 Key strengths 308
14.1.1.4.2 Strategic choices 308
14.1.1.4.3 Weaknesses & competitive threats 308
14.1.2 WUXI BIOLOGICS 309
14.1.2.1 Business overview 309
14.1.2.2 Services offered 311
14.1.2.3 Recent developments 312
14.1.2.3.1 Deals 312
14.1.2.3.2 Expansions 312
14.1.2.4 MnM view 313
14.1.2.4.1 Key strengths 313
14.1.2.4.2 Strategic choices 313
14.1.2.4.3 Weaknesses & competitive threats 313
14.1.3 SAMSUNG BIOLOGICS 314
14.1.3.1 Business overview 314
14.1.3.2 Services offered 316
14.1.3.3 Recent developments 316
14.1.3.3.1 Service launches 316
14.1.3.3.2 Deals 316
14.1.3.3.3 Expansions 317
14.1.3.4 MnM view 318
14.1.3.4.1 Key strengths 318
14.1.3.4.2 Strategic choices 318
14.1.3.4.3 Weaknesses & competitive threats 318
14.1.4 THERMO FISHER SCIENTIFIC INC. 319
14.1.4.1 Business overview 319
14.1.4.2 Services offered 321
14.1.4.3 Recent developments 321
14.1.4.3.1 Deals 321
14.1.4.4 MnM view 322
14.1.4.4.1 Key strengths 322
14.1.4.4.2 Strategic choices 322
14.1.4.4.3 Weaknesses & competitive threats 322
14.1.5 ABBVIE INC. 323
14.1.5.1 Business overview 323
14.1.5.2 Services offered 324
14.1.6 CATALENT, INC. 325
14.1.6.1 Business overview 325
14.1.6.2 Services offered 326
14.1.6.3 Recent developments 328
14.1.6.3.1 Deals 328
14.1.6.3.2 Expansions 328
14.1.6.4 MnM view 329
14.1.6.4.1 Key strengths 329
14.1.6.4.2 Strategic choices 329
14.1.6.4.3 Weaknesses & competitive threats 329
14.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 330
14.1.7.1 Business overview 330
14.1.7.2 Services offered 332
14.1.7.3 Recent developments 333
14.1.7.3.1 Other developments 333
14.1.8 FUJIFILM HOLDINGS CORPORATION 334
14.1.8.1 Business overview 334
14.1.8.2 Services offered 335
14.1.8.3 Recent developments 336
14.1.8.3.1 Deals 336
14.1.8.3.2 Expansions 337
14.1.9 EUROFINS SCIENTIFIC 338
14.1.9.1 Business overview 338
14.1.9.2 Services offered 340
14.1.9.3 Recent developments 340
14.1.9.3.1 Expansions 340
14.1.10 GENSCRIPT BIOTECH CORPORATION 342
14.1.10.1 Business overview 342
14.1.10.2 Services offered 344
14.1.10.3 Recent developments 344
14.1.10.3.1 Service launches 344
14.1.10.3.2 Deals 345
14.1.10.3.3 Expansions 345
14.1.11 AGC INC. 346
14.1.11.1 Business overview 346
14.1.11.2 Services offered 347
14.1.11.3 Recent developments 348
14.1.11.3.1 Deals 348
14.1.11.3.2 Expansions 349
14.1.12 MERCK KGAA 350
14.1.12.1 Business overview 350
14.1.12.2 Services offered 351
14.1.12.3 Recent developments 352
14.1.12.3.1 Deals 352
14.1.12.3.2 Expansions 352
14.1.13 JSR CORPORATION 353
14.1.13.1 Business overview 353
14.1.13.2 Services offered 355
14.1.13.3 Recent developments 355
14.1.13.3.1 Expansions 355
14.1.14 IDT BIOLOGIKA 356
14.1.14.1 Business overview 356
14.1.14.2 Services offered 356
14.1.14.3 Recent developments 357
14.1.14.3.1 Other developments 357
14.1.15 AJINOMOTO BIO-PHARMA 358
14.1.15.1 Business overview 358
14.1.15.2 Services offered 359
14.1.15.3 Recent developments 359
14.1.15.3.1 Deals 359
14.1.16 AGILENT TECHNOLOGIES INC. 360
14.1.16.1 Business overview 360
14.1.16.2 Services offered 361
14.1.16.3 Recent developments 362
14.1.16.3.1 Deals 362
14.1.17 ASAHI KASEI CORPORATION 363
14.1.17.1 Business overview 363
14.1.17.2 Services offered 364
14.1.17.3 Recent developments 365
14.1.17.3.1 Deals 365
14.2 OTHER PLAYERS 366
14.2.1 ONESOURCE PHARMA SOLUTIONS 366
14.2.2 RECIPHARM AB 366
14.2.3 EMERGENT BIOSOLUTIONS 367
14.2.4 SHANGHAI FOSUN PHARMACEUTICAL CO., LTD. 368
14.2.5 LOTTE BIOLOGICS 369
14.2.6 CURIA GLOBAL, INC. 369
14.2.7 POLYPLUS TRANSFECTION 370
14.2.8 ALDEVRON LLC 370
14.2.9 MINAPHARM PHARMACEUTICALS 370
14.2.10 RENTSCHLER BIOPHARMA SE 372
14.2.11 PORTON PHARMA SOLUTIONS 373
14.2.12 CELLARES, INC. 373
14.2.13 MABPLEX INTERNATIONAL CO., LTD. 374
14.2.14 ASYMCHEM INC. 374
15 APPENDIX 375
15.1 DISCUSSION GUIDE 375
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 378
15.3 CUSTOMIZATION OPTIONS 380
15.4 RELATED REPORTS 381
15.5 AUTHOR DETAILS 382
LIST OF TABLES
TABLE 1 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
INCLUSIONS & EXCLUSIONS 36
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 49
TABLE 3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RISK ANALYSIS 51
TABLE 4 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
IMPACT ANALYSIS OF MARKET DYNAMICS 61
TABLE 5 LIST OF KEY BIOSIMILARS APPROVED, 2023–2025 62
TABLE 6 LIST OF EXPANSIONS BY TOP COMPANIES 67
TABLE 7 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
ROLE IN ECOSYSTEM 75
TABLE 8 NUMBER OF PATENTS FILED IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2014–2024 77
TABLE 9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
INDICATIVE LIST OF PATENTS, 2022 79
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 14 COUNTRY-WISE REGULATORY SCENARIO FOR CONTRACT MANUFACTURING 82
TABLE 15 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2025–2026) 85
TABLE 16 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS 86
TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES (%) 88
TABLE 18 KEY BUYING CRITERIA FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES, BY END USER 89
TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 93
TABLE 20 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE,
2023–2030 (USD MILLION) 98
TABLE 21 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION) 99
TABLE 22 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 100
TABLE 23 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 100
TABLE 24 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 25 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 26 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION) 102
TABLE 27 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD MILLION) 103
TABLE 28 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY,
2023–2030 (USD MILLION) 103
TABLE 29 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 30 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 31 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 32 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD MILLION) 105
TABLE 33 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD MILLION) 106
TABLE 34 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY,
2023–2030 (USD MILLION) 106
TABLE 35 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 36 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 37 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 38 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD MILLION) 108
TABLE 39 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION) 109
TABLE 40 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 41 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 42 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 43 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 44 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION) 111
TABLE 45 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE,
2023–2030 (USD MILLION) 113
TABLE 46 BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY REGION,
2023–2030 (USD MILLION) 114
TABLE 47 NORTH AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 48 EUROPE: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 49 ASIA PACIFIC: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 50 LATIN AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 51 MIDDLE EAST: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET,
BY REGION, 2023–2030 (USD MILLION) 117
TABLE 52 BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY REGION,
2023–2030 (USD MILLION) 118
TABLE 53 NORTH AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 54 EUROPE: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 55 ASIA PACIFIC: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 56 LATIN AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 57 MIDDLE EAST: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET,
BY REGION, 2023–2030 (USD MILLION) 120
TABLE 58 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 122
TABLE 59 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION) 124
TABLE 60 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 61 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 62 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 63 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 64 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION) 126
TABLE 65 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION) 127
TABLE 66 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 67 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 68 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 69 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 70 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION) 129
TABLE 71 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 131
TABLE 72 TYPES OF MAMMALIAN EXPRESSION SYSTEMS 132
TABLE 73 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 132
TABLE 74 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY,
2023–2030 (USD MILLION) 133
TABLE 75 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 76 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 77 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 78 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 135
TABLE 79 TYPES OF MICROBIAL EXPRESSION SYSTEMS AND THEIR APPLICATIONS 135
TABLE 80 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 137
TABLE 81 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY,
2023–2030 (USD MILLION) 137
TABLE 82 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 83 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY,
2023–2030 (USD MILLION) 138
TABLE 84 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY,
2023–2030 (USD MILLION) 139
TABLE 85 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION,
2023–2030 (USD MILLION) 139
TABLE 86 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 141
TABLE 87 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 142
TABLE 88 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 89 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 90 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 91 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 92 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 144
TABLE 93 FDA-APPROVED CAR T-CELL THERAPIES 145
TABLE 94 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023–2030 (USD MILLION) 145
TABLE 95 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 96 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 97 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 98 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 99 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023–2030 (USD MILLION) 148
TABLE 100 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2023–2030 (USD MILLION) 149
TABLE 101 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 102 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 103 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 104 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 105 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2023–2030 (USD MILLION) 151
TABLE 106 NIH FUNDING FOR VACCINE RESEARCH, 2018–2024 (USD MILLION) 152
TABLE 107 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES,
BY REGION, 2023–2030 (USD MILLION) 152
TABLE 108 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 109 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 110 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 111 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 112 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR VACCINES, BY REGION, 2023–2030 (USD MILLION) 155
TABLE 113 EXAMPLES OF PEPTIDE THERAPEUTICS 156
TABLE 114 COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE 156
TABLE 115 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD MILLION) 157
TABLE 116 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY,
2023–2030 (USD MILLION) 157
TABLE 117 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 118 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 119 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 120 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD MILLION) 159
TABLE 121 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION) 160
TABLE 122 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 123 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 124 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 125 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 126 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION) 162
TABLE 127 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 164
TABLE 128 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY,
BY REGION, 2023–2030 (USD MILLION) 166
TABLE 129 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 130 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 131 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 132 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 133 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 168
TABLE 134 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION) 169
TABLE 135 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 136 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 137 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 138 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 139 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION) 171
TABLE 140 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 172
TABLE 141 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 142 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 143 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 144 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 145 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 174
TABLE 146 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION) 175
TABLE 147 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 148 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 149 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 150 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 151 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION) 178
TABLE 152 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 179
TABLE 153 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 154 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 155 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 156 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 157 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 181
TABLE 158 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY,
BY REGION, 2023–2030 (USD MILLION) 182
TABLE 159 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 160 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 161 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 162 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 163 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR NEUROLOGY, BY REGION 2023–2030 (USD MILLION) 184
TABLE 164 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 185
TABLE 165 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 166 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 167 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 168 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 169 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 187
TABLE 170 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION,
2023–2030 (USD MILLION) 189
TABLE 171 NORTH AMERICA: KEY MACROINDICATORS 192
TABLE 172 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 173 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 193
TABLE 174 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 175 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 194
TABLE 176 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 194
TABLE 177 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 195
TABLE 178 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 195
TABLE 179 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 196
TABLE 180 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE,
2023–2030 (USD MILLION) 197
TABLE 181 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 197
TABLE 182 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 197
TABLE 183 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 198
TABLE 184 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 198
TABLE 185 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 199
TABLE 186 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 187 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 200
TABLE 188 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 200
TABLE 189 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 201
TABLE 190 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 201
TABLE 191 EUROPE: KEY MACROINDICATORS 203
TABLE 192 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 193 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 204
TABLE 194 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 195 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 205
TABLE 196 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 205
TABLE 197 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 206
TABLE 198 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 206
TABLE 199 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 207
TABLE 200 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 208
TABLE 201 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 208
TABLE 202 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 208
TABLE 203 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 209
TABLE 204 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 209
TABLE 205 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 210
TABLE 206 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE,
2023–2030 (USD MILLION) 211
TABLE 207 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 211
TABLE 208 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 211
TABLE 209 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 212
TABLE 210 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 212
TABLE 211 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 213
TABLE 212 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 214
TABLE 213 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 214
TABLE 214 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 214
TABLE 215 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 215
TABLE 216 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 215
TABLE 217 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 216
TABLE 218 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 217
TABLE 219 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 217
TABLE 220 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 217
TABLE 221 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 218
TABLE 222 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 218
TABLE 223 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 219
TABLE 224 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 220
TABLE 225 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 220
TABLE 226 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 220
TABLE 227 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 221
TABLE 228 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 221
TABLE 229 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 222
TABLE 230 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 222
TABLE 231 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 223
TABLE 232 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 223
TABLE 233 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 224
TABLE 234 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 224
TABLE 235 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 225
TABLE 236 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 225
TABLE 237 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 226
TABLE 238 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 226
TABLE 239 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 227
TABLE 240 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 227
TABLE 241 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 228
TABLE 242 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 228
TABLE 243 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 229
TABLE 244 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 229
TABLE 245 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 230
TABLE 246 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 230
TABLE 247 ASIA PACIFIC: KEY MACROINDICATORS 233
TABLE 248 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 233
TABLE 249 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 234
TABLE 250 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 234
TABLE 251 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 235
TABLE 252 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 235
TABLE 253 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 236
TABLE 254 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 236
TABLE 255 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 238
TABLE 256 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 238
TABLE 257 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 239
TABLE 258 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 239
TABLE 259 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 240
TABLE 260 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 240
TABLE 261 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 241
TABLE 262 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 242
TABLE 263 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 242
TABLE 264 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 242
TABLE 265 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 243
TABLE 266 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 243
TABLE 267 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 244
TABLE 268 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 245
TABLE 269 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 245
TABLE 270 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 245
TABLE 271 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 246
TABLE 272 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 246
TABLE 273 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 247
TABLE 274 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 248
TABLE 275 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 248
TABLE 276 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 248
TABLE 277 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 249
TABLE 278 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 249
TABLE 279 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 250
TABLE 280 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 251
TABLE 281 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 251
TABLE 282 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 251
TABLE 283 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 252
TABLE 284 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 252
TABLE 285 LATIN AMERICA: KEY MACROINDICATORS 254
TABLE 286 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 254
TABLE 287 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 255
TABLE 288 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 255
TABLE 289 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 256
TABLE 290 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 256
TABLE 291 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 257
TABLE 292 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 257
TABLE 293 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 258
TABLE 294 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 258
TABLE 295 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 259
TABLE 296 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 259
TABLE 297 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 260
TABLE 298 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 260
TABLE 299 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 261
TABLE 300 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 261
TABLE 301 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 262
TABLE 302 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 262
TABLE 303 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 263
TABLE 304 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 263
TABLE 305 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 264
TABLE 306 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 264
TABLE 307 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 265
TABLE 308 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 265
TABLE 309 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 266
TABLE 310 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 266
TABLE 311 MIDDLE EAST: KEY MACROINDICATORS 268
TABLE 312 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY REGION, 2023–2030 (USD MILLION) 268
TABLE 313 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 268
TABLE 314 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 269
TABLE 315 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 269
TABLE 316 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 269
TABLE 317 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 270
TABLE 318 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 270
TABLE 319 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2023–2030 (USD MILLION) 271
TABLE 320 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY TYPE, 2023–2030 (USD MILLION) 272
TABLE 321 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 272
TABLE 322 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2023–2030 (USD MILLION) 273
TABLE 323 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 273
TABLE 324 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 274
TABLE 325 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 275
TABLE 326 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 275
TABLE 327 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 276
TABLE 328 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 276
TABLE 329 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 277
TABLE 330 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 277
TABLE 331 AFRICA: KEY MACROINDICATORS 279
TABLE 332 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 279
TABLE 333 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 280
TABLE 334 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 280
TABLE 335 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 281
TABLE 336 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2023–2030 (USD MILLION) 281
TABLE 337 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 282
TABLE 338 STRATEGIES DEPLOYED BY KEY PLAYERS 283
TABLE 339 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
DEGREE OF COMPETITION 287
TABLE 340 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGION FOOTPRINT 292
TABLE 341 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
SERVICE TYPE FOOTPRINT 293
TABLE 342 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
MOLECULE TYPE FOOTPRINT 294
TABLE 343 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
THERAPEUTIC AREA FOOTPRINT 295
TABLE 344 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
DETAILED LIST OF KEY SMES/STARTUPS 298
TABLE 345 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, 2024 299
TABLE 346 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025 302
TABLE 347 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
DEALS, JANUARY 2022–JUNE 2025 302
TABLE 348 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
EXPANSIONS, JANUARY 2022– JUNE 2025 303
TABLE 349 LONZA: COMPANY OVERVIEW 304
TABLE 350 LONZA: SERVICES OFFERED 306
TABLE 351 LONZA: DEALS, JANUARY 2022–JUNE 2025 307
TABLE 352 LONZA: EXPANSIONS, JANUARY 2022–JUNE 2025 308
TABLE 353 WUXI BIOLOGICS: COMPANY OVERVIEW 309
TABLE 354 WUXI BIOLOGICS: SERVICES OFFERED 311
TABLE 355 WUXI BIOLOGICS: DEALS, JANUARY 2022–JUNE 2025 312
TABLE 356 WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022– JUNE 2025 312
TABLE 357 SAMSUNG BIOLOGICS: COMPANY OVERVIEW 314
TABLE 358 SAMSUNG BIOLOGICS: SERVICES OFFERED 316
TABLE 359 SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025 316
TABLE 360 SAMSUNG BIOLOGICS: DEALS, JANUARY 2022–JUNE 2025 316
TABLE 361 SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2022–JUNE 2025 317
TABLE 362 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 319
TABLE 363 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 321
TABLE 364 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JUNE 2025 321
TABLE 365 ABBVIE INC.: COMPANY OVERVIEW 323
TABLE 366 ABBVIE INC.: SERVICES OFFERED 324
TABLE 367 CATALENT, INC.: COMPANY OVERVIEW 325
TABLE 368 CATALENT, INC.: SERVICES OFFERED 326
TABLE 369 CATALENT, INC.: DEALS, JANUARY 2022–JUNE 2025 328
TABLE 370 CATALENT, INC.: EXPANSIONS, JANUARY 2022–JUNE 2025 328
TABLE 371 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 330
TABLE 372 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SERVICES OFFERED 332
TABLE 373 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 333
TABLE 374 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW 334
TABLE 375 FUJIFILM HOLDINGS CORPORATION: SERVICES OFFERED 335
TABLE 376 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2022–JUNE 2025 336
TABLE 377 FUJIFILM HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025 337
TABLE 378 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 338
TABLE 379 EUROFINS SCIENTIFIC: SERVICES OFFERED 340
TABLE 380 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2022–JUNE 2025 340
TABLE 381 GENSCRIPT BIOTECH CORPORATION: COMPANY OVERVIEW 342
TABLE 382 GENSCRIPT BIOTECH CORPORATION: SERVICES OFFERED 344
TABLE 383 GENSCRIPT BIOTECH CORPORATION: SERVICE LAUNCHES,
JANUARY 2022–JUNE 2025 344
TABLE 384 GENSCRIPT BIOTECH CORPORATION: DEALS, JANUARY 2022–JUNE 2025 345
TABLE 385 GENSCRIPT BIOTECH CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025 345
TABLE 386 ACG INC.: COMPANY OVERVIEW 346
TABLE 387 AGC INC.: SERVICES OFFERED 347
TABLE 388 AGC INC: DEALS, JANUARY 2022–JUNE 2025 348
TABLE 389 AGC INC.: EXPANSIONS, JANUARY 2022–JUNE 2025 349
TABLE 390 MERCK KGAA: COMPANY OVERVIEW 350
TABLE 391 MERCK KGAA: SERVICES OFFERED 351
TABLE 392 MERCK KGAA: DEALS, JANUARY 2022–JUNE 2025 352
TABLE 393 MERCK KGAA: EXPANSIONS, JANUARY 2022–JUNE 2025 352
TABLE 394 JSR CORPORATION: COMPANY OVERVIEW 353
TABLE 395 JSR CORPORATION: SERVICES OFFERED 355
TABLE 396 JSR CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025 355
TABLE 397 IDT BIOLOGIKA: COMPANY OVERVIEW 356
TABLE 398 IDT BIOLOGIKA: SERVICES OFFERED 356
TABLE 399 IDT BIOLOGIKA: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 357
TABLE 400 AJINOMOTO BIO-PHARMA: COMPANY OVERVIEW 358
TABLE 401 AJINOMOTO BIO-PHARMA: SERVICES OFFERED 359
TABLE 402 AJINOMOTO BIO-PHARMA: DEALS, JANUARY 2022–JUNE 2025 359
TABLE 403 AGILENT TECHNOLOGIES INC.: COMPANY OVERVIEW 360
TABLE 404 AGILENT TECHNOLOGIES INC.: SERVICES OFFERED 361
TABLE 405 AGILENT TECHNOLOGIES INC.: DEALS, JANUARY 2022–JUNE 2025 362
TABLE 406 ASAHI KASEI CORPORATION: COMPANY OVERVIEW 363
TABLE 407 ASAHI KASEI CORPORATION: SERVICES OFFERED 364
TABLE 408 ASAHI KASEI CORPORATION: DEALS, JANUARY 2022–JUNE 2025 365
TABLE 409 ONESOURCE PHARMA SOLUTIONS: COMPANY OVERVIEW 366
TABLE 410 RECIPHARM AB: COMPANY OVERVIEW 366
TABLE 411 EMERGENT: COMPANY OVERVIEW 367
TABLE 412 SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 368
TABLE 413 LOTTE BIOLOGICS: COMPANY OVERVIEW 369
TABLE 414 CURIA GLOBAL, INC.: COMPANY OVERVIEW 369
TABLE 415 POLYPLUS TRANSFECTION: COMPANY OVERVIEW 370
TABLE 416 ALDEVRON LLC: COMPANY OVERVIEW 370
TABLE 417 MINAPHARM PHARMACEUTICALS: COMPANY OVERVIEW 370
TABLE 418 RENTSCHLER BIOPHARMA SE: COMPANY OVERVIEW 372
TABLE 419 PORTON PHARMA SOLUTIONS: COMPANY OVERVIEW 373
TABLE 420 CELLARES, INC.: COMPANY OVERVIEW 373
TABLE 421 MABPLEX INTERNATIONAL CO., LTD.: COMPANY OVERVIEW 374
TABLE 422 ASYMCHEM INC.: COMPANY OVERVIEW 374
LIST OF FIGURES
FIGURE 1 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
SEGMENTATION & REGIONAL SCOPE 35
FIGURE 2 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: YEARS CONSIDERED 37
FIGURE 3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH DESIGN 39
FIGURE 4 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
KEY DATA FROM SECONDARY SOURCES 41
FIGURE 5 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
BREAKDOWN OF PRIMARY INTERVIEWS 42
FIGURE 6 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 43
FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION:
BOTTOM-UP APPROACH (2024) 44
FIGURE 8 REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC. (2024) 44
FIGURE 9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE VALIDATION FROM PRIMARY SOURCES 46
FIGURE 10 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
TOP-DOWN APPROACH 47
FIGURE 11 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS 48
FIGURE 12 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
DATA TRIANGULATION 50
FIGURE 13 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE,
2025 VS. 2030 (USD MILLION) 52
FIGURE 14 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE,
2025 VS. 2030 (USD MILLION) 53
FIGURE 15 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE,
2025 VS. 2030 (USD MILLION) 53
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF BIOPHARMACEUTICAL CONTRACT
MANUFACTURING MARKET 54
FIGURE 17 INCREASING APPROVALS OF BIOLOGICS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 56
FIGURE 18 COMMERCIAL OPERATIONS SEGMENT TO ACCOUNT FOR
LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025 57
FIGURE 19 ONCOLOGY SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2030 57
FIGURE 20 MONOCLONAL ANTIBODIES TO CONTINUE TO DOMINATE MARKET IN 2030 58
FIGURE 21 ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET DURING FORECAST PERIOD 59
FIGURE 22 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
FIGURE 23 PERSONALIZED MEDICINES (% OF ALL FDA-APPROVED DRUGS), 2015–2024 65
FIGURE 24 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72
FIGURE 25 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
VALUE CHAIN ANALYSIS 74
FIGURE 26 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ECOSYSTEM MAP 75
FIGURE 27 PATENT ANALYSIS OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, JANUARY 2014–DECEMBER 2024 78
FIGURE 28 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
PORTER’S FIVE FORCES ANALYSIS 86
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES 88
FIGURE 30 KEY BUYING CRITERIA FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES, BY END USER 89
FIGURE 31 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
INVESTMENT & FUNDING SCENARIO 90
FIGURE 32 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT
MANUFACTURING MARKET SNAPSHOT 191
FIGURE 33 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT 232
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2020–2024 (USD MILLION) 285
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET (2024) 287
FIGURE 36 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 290
FIGURE 37 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
COMPANY FOOTPRINT 291
FIGURE 38 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
COMPANY EVALUATION MATRIX (SMES/STARTUPS), 2024 297
FIGURE 39 EV/EBITDA OF KEY VENDORS 300
FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 300
FIGURE 41 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET:
BRAND/PRODUCT COMPARATIVE ANALYSIS 301
FIGURE 42 LONZA: COMPANY SNAPSHOT (2024) 305
FIGURE 43 WUXI BIOLOGICS: COMPANY SNAPSHOT (2024) 310
FIGURE 44 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2024) 315
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 320
FIGURE 46 ABBVIE INC.: COMPANY SNAPSHOT (2024) 324
FIGURE 47 CATALENT, INC.: COMPANY SNAPSHOT (2024) 326
FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024) 331
FIGURE 49 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024) 335
FIGURE 50 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 339
FIGURE 51 SGENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2024) 343
FIGURE 52 AGC INC.: COMPANY SNAPSHOT (2024) 347
FIGURE 53 MERCK KGAA: COMPANY SNAPSHOT (2024) 351
FIGURE 54 JSR CORPORATION: COMPANY SNAPSHOT (2024) 354
FIGURE 55 AJINOMOTO BIO-PHARMA: COMPANY SNAPSHOT (2024) 359
FIGURE 56 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2024) 361
FIGURE 57 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2024) 364
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11